

PATENT
0508-1063-1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: DREYFUS et al.
Appl. No.: **NEW DIVISIONAL** Group: Unassigned
Filed: January 30, 2004 Examiner: Unassigned
For: METHOD FOR THE TREATMENT OR DIAGNOSIS OF
HUMAN PATHOLOGIES WITH DISSEMINATED OR
DIFFICULT TO ACCESS CELLS OR TISSUES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 30, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

08/924,830

U.S. Filing Date(s)

September 5, 1997

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.


If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By


Andrew J. Patch, Reg. No. 32,925

AJP/psf
0508-1063-1

745 South 23rd Street
Arlington, Virginia 22202
(703) 521-2297

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

Revised January 9, 2003

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Attorney Docket No.: 0508-1063-1	Application No.: NEW DIVISIONAL
	Applicant: DREYFUS et al.	
	Filing Date: January 30, 2004	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Curiel, D.T., et al., 1996, "Gene Therapy Approaches for Inherited and Acquired Lung Diseases", Am. J. Respir. Cell Mol. Biol. 14:1-18
		Parrish, E.P., et al., 1996, "Targeted widespread sites of damages in dystrophic muscle: engrafted macrophages as potential shuttles", Gene Therapy 3:13-20
		Kan, U.J. 1998, "Potential of Gene Therapy for Parkinson's Disease: Neurobiologic Issue and New Developments in Gene Transfer Methodologies", Movement Disorders 13(S1):59-72
		Martin, J. B., 1995, "Gene therapy and pharmacological treatment of inherited neurological disorders", Trends Biotech. 13(1):28-35 (abstract provided)
		Shvaloff, A., et al., 1996, "Lines of therapeutics research in Alzheimer's disease", Psychopharm. Bull. 32(3):343-52 (abstract provided)
		Bankiewicz, K. S., et al., 1997, "Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease", Exp. Neurol. 144(1):147-56 (abstract provided)
		Horellou, P. and J. Mallet, 1997, "Gene therapy for Parkinson's disease", Mol. Neurobiol. 15(2):241-56 (abstract provided)

EXAMINER:	DATE CONSIDERED
-----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* Abstract provided for the Examiner's convenience